By Forum Bhagat, Managing Director of Novo Medi Sciences (Novo Group)

In today’s healthcare landscape, the critical care segment is one of the indispensable areas in managing life-threatening conditions, ensuring patient survival, and facilitating recovery. The efficiency of critical care therapy is highly dependent on several factors, such as the adequacy of Intensive Care Unit (ICU) facilities, stringent quality standards, the mounting challenge of antimicrobial resistance, inventive research and development (R&D), robust cold chain logistics, and the impact of Government healthcare initiatives.
 
Exploring the current scenario in the critical care segment will give us insights into its adequacy and ways of future empowerment.
 
ICU Admissions and Infrastructure
 
Even today, India faces a significant challenge in critical care infrastructure. The country has approximately 95,000 ICU beds, predominantly in private facilities in urban centres, with 2.3 ICU beds for every 100,000 people.  A stark disparity is also highlighted in the distribution of critical care facilities, with the rural areas having almost 1/3rd the availability of hospital beds compared to the urban areas. In contrast, countries like the United States have approximately 34.7 ICU beds per 100,000 people. These statistics highlight the urgent need to expand and upgrade ICU services to meet the growing demands and ensure equal access across the nation.
 
Rising Antimicrobial Resistance and Disease Burden
 
In India, antimicrobial resistance (AMR) is an ever-increasing crisis, especially in the critical care area. The ever-rising AMR is leading to complications of the treatment protocols, prolonged hospital stays, higher mortality rates, and an increasing burden on resources. A study conducted by the Indian Council of Medical Research (ICMR) demonstrated an escalating risk in terms of the emergence of resistant pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii, which are proving resistant to carbapenems among ICU patients with bloodstream infections. Staphylococcus aureus and Enterococcus faecium have further exhibited resistance to oxacillin and vancomycin.
 
Quality of Medicines and Schedule M Compliance
 
In the critical care segment, quality of the medicines is of a paramount importance, as it influences the patient and treatment outcomes, and is often a life-saver. Thus, it is always under a scanner. Having recognized this, the Government of India mandated Schedule M under the Drugs and Cosmetics Rules, 1945, which has aligned Good Manufacturing Practices (GMP) with international standards. This move has led to governance of stringent quality control, and adoption of advanced manufacturing technologies, which ensure global quality products with international safety and efficacy benchmarks.
 
Importance of Research and Development
 
Continuous R&D is the cornerstone of advancements in critical care medicines. Investments in R&D facilitate the development of innovative therapies, address emerging health threats, and improve patient outcomes. The revised Schedule M underscores the significance of R&D by introducing stricter GMP norms that affect all aspects of pharmaceutical manufacturing, including research and development.

 
Pradhan Mantri Jan Arogya Yojana (PM-JAY) and its impact
 
Government schemes like the PM-JAY, launched in 2018, have led to a significant increase in the demand for quality medicines and healthcare services across the urban and rural sectors of India since these were launched to provide health coverage to over 500 million economically challenged individuals in India. A rigorous strengthening of the critical care infrastructure and processes to provide quality medicines in the critical care segment is the need of the times^.

 
Future Desirable Progress
 
To strengthen India’s growing critical care landscape, a multifaceted approach is most essential. The above discussed insufficiencies will need to be addressed which will undoubtedly strengthen the critical care segment, leading to improved patient outcomes, reduced mortality rates, and a more resilient healthcare system equipped to handle future challenges.
 
At Novo Medi (Novo Group), we are keen to play a vital role in public health and set high standards in healthcare quality and accessibility. With one of our core visions to strengthen the critical care sector in India, we are taking essential steps towards bringing revolutionary changes by introducing several innovative drugs and combinations that are easy to access and affordable.
 
In 2024 – 2025, we will continue our mission to cater to critical healthcare challenges with innovative solutions, such as developing World’s first meropenem and sulbactam injection for serious bacterial infections, the reintroducing NEXICLOX DS 250mg, a trusted Cloxacillin syrup in the event of rising multi-drug resistance (MDR) against susceptible Staphylococcus infections, in addition to conducting extensive research on vaccines for Meningitis and Pneumonia in Phase 3 trials. We are known to ensure the highest quality products using EUGMP standard-compliant quality processes, raw materials, etc. This underscores our commitment to be a forerunner in tackling critical diseases across all age groups. Novo Medi (Novo Group) follows stringent testing of samples from distribution centres of all parts of India, even in the most remote locations, to check whether quality is maintained. This has ensured a record of ‘No-batch’ recall ever. This is even more important considering the temperature fluctuations across India’s geography and the possible electricity cuts in some areas. We believe in offering continuous patient benefits through constant innovation.
 
Novo Medi Sciences (Novo Group), with a legacy of over 75 years, continues to leverage today’s technology and medical insights to achieve responsible, impactful innovation in the critical care segment.
 
The critical care segment is a cornerstone of the healthcare system in India. Ensuring quality, effectiveness, and safety requires an all-inclusive approach involving infrastructure development, regulatory compliance, innovation, meticulous logistical management, and supportive healthcare policies. Such comprehensive efforts are bound to make India’s critical care system adequate to handle the challenges of a critical care segment and save more lives.